Linked Life Data

12519547

Source:http://linkedlifedata.com/resource/pubmed/id/12519547

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2003-1-9
pubmed:abstractText
The newer 5-ASA preparations were intended to avoid the adverse effects of SASP while maintaining its therapeutic benefits. The efficacy and safety of 5-ASA preparations have been evaluated in numerous clinical trials that have often lacked sufficient statistical power to arrive at definitive conclusions. Previously, it was found that newer 5-ASA drugs were more effective than placebo but no more effective than SASP in inducing remission in ulcerative colitis. This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety of 5-ASA preparations in terms of more precise outcome measures.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1469-493X
pubmed:author
pubmed:issnType
Electronic
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
CD000544
pubmed:dateRevised
2006-6-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
pubmed:affiliation
Division of Gastroenterology, University of Calgary, Foothills Hospital, 1751 3330 Hospital Drive N W, Calgary, AB, Canada, T2N 4N1. lsutherl@acs.ucalgary.ca
pubmed:publicationType
Journal Article, Review